CG Oncology (CG Oncology) Debt-to-EBITDA : -0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CG Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.22 Mil. CG Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.18 Mil. CG Oncology's annualized EBITDA for the quarter that ended in Mar. 2024 was $-89.86 Mil. CG Oncology's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CG Oncology's Debt-to-EBITDA or its related term are showing as below:

CGON' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.22 Med: -0.45 Max: -0.01
Current: -0.01

During the past 3 years, the highest Debt-to-EBITDA Ratio of CG Oncology was -0.01. The lowest was -1.22. And the median was -0.45.

CGON's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.37 vs CGON: -0.01

CG Oncology Debt-to-EBITDA Historical Data

The historical data trend for CG Oncology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Debt-to-EBITDA Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

-1.22

-0.45

-0.01

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial			-0.43	-	N/A	-0.01	-

Competitive Comparison of CG Oncology's Debt-to-EBITDA

For the Biotechnology subindustry, CG Oncology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CG Oncology's Debt-to-EBITDA falls into.

CG Oncology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CG Oncology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.217	+	0.244)	/	-55.432
	=	-0.01

CG Oncology's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.22	+	0.184)	/	-89.86
	=	-0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

CG Oncology (NAS:CGON) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

CG Oncology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CG Oncology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024